Logo image of ALDMS.PA

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) Stock Fundamental Analysis

EPA:ALDMS - FR0012202497 - Common Stock

1.355 EUR
+0.02 (+1.5%)
Last: 9/11/2025, 7:00:00 PM
Fundamental Rating

2

ALDMS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALDMS have multiple concerns. ALDMS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALDMS has reported negative net income.
In the past year ALDMS had a positive cash flow from operations.
In the past 5 years ALDMS always reported negative net income.
In multiple years ALDMS reported negative operating cash flow during the last 5 years.
ALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

1.2 Ratios

ALDMS has a worse Return On Assets (-5.34%) than 65.52% of its industry peers.
Looking at the Return On Equity, with a value of -22.44%, ALDMS is doing worse than 67.24% of the companies in the same industry.
Industry RankSector Rank
ROA -5.34%
ROE -22.44%
ROIC N/A
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ALDMS.PA Yearly ROA, ROE, ROICALDMS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

ALDMS has a Gross Margin of 39.92%. This is in the lower half of the industry: ALDMS underperforms 75.86% of its industry peers.
ALDMS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ALDMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
ALDMS.PA Yearly Profit, Operating, Gross MarginsALDMS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

ALDMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALDMS has more shares outstanding
The number of shares outstanding for ALDMS has been increased compared to 5 years ago.
The debt/assets ratio for ALDMS has been reduced compared to a year ago.
ALDMS.PA Yearly Shares OutstandingALDMS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ALDMS.PA Yearly Total Debt VS Total AssetsALDMS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of 1.07, we must say that ALDMS is in the distress zone and has some risk of bankruptcy.
ALDMS's Altman-Z score of 1.07 is on the low side compared to the rest of the industry. ALDMS is outperformed by 63.79% of its industry peers.
The Debt to FCF ratio of ALDMS is 5.57, which is a neutral value as it means it would take ALDMS, 5.57 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.57, ALDMS is in line with its industry, outperforming 53.45% of the companies in the same industry.
A Debt/Equity ratio of 0.90 indicates that ALDMS is somewhat dependend on debt financing.
ALDMS has a worse Debt to Equity ratio (0.90) than 79.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.57
Altman-Z 1.07
ROIC/WACCN/A
WACC6.87%
ALDMS.PA Yearly LT Debt VS Equity VS FCFALDMS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

ALDMS has a Current Ratio of 1.29. This is a normal value and indicates that ALDMS is financially healthy and should not expect problems in meeting its short term obligations.
ALDMS has a worse Current ratio (1.29) than 63.79% of its industry peers.
ALDMS has a Quick Ratio of 1.29. This is a bad value and indicates that ALDMS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALDMS has a worse Quick ratio (0.67) than 75.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 0.67
ALDMS.PA Yearly Current Assets VS Current LiabilitesALDMS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

ALDMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
Looking at the last year, ALDMS shows a quite strong growth in Revenue. The Revenue has grown by 9.29% in the last year.
The Revenue has been growing by 8.24% on average over the past years. This is quite good.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87%
Revenue 1Y (TTM)9.29%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%8.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ALDMS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.69% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.57%
Revenue Next 2Y13.15%
Revenue Next 3Y12.74%
Revenue Next 5Y12.69%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALDMS.PA Yearly Revenue VS EstimatesALDMS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
ALDMS.PA Yearly EPS VS EstimatesALDMS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2026 2027 0 0.05 -0.05 0.1 -0.1 -0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDMS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDMS.PA Price Earnings VS Forward Price EarningsALDMS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

96.55% of the companies in the same industry are more expensive than ALDMS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 10.03
EV/EBITDA N/A
ALDMS.PA Per share dataALDMS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALDMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIAGNOSTIC MEDICAL SYSTEMS

EPA:ALDMS (9/11/2025, 7:00:00 PM)

1.355

+0.02 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.23%
Ins Owner ChangeN/A
Market Cap36.11M
Analysts86
Price Target2.09 (54.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.13%
PT rev (3m)13.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-100%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.55%
Revenue NY rev (3m)-3.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.78
P/FCF 10.03
P/OCF 10.03
P/B 2.81
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.14
FCFY9.97%
OCF(TTM)0.14
OCFY9.97%
SpS1.73
BVpS0.48
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.34%
ROE -22.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.92%
FCFM 7.82%
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
F-Score6
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.57
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 0.67
Altman-Z 1.07
F-Score6
WACC6.87%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.29%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%8.7%
Revenue Next Year15.57%
Revenue Next 2Y13.15%
Revenue Next 3Y12.74%
Revenue Next 5Y12.69%
EBIT growth 1Y35.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1225%
EBIT Next 3Y158.38%
EBIT Next 5Y101.17%
FCF growth 1Y318.91%
FCF growth 3YN/A
FCF growth 5Y58.15%
OCF growth 1Y318.91%
OCF growth 3YN/A
OCF growth 5Y58.15%